Eli Lilly is aggressively expanding its drug pipeline beyond metabolic treatments. The pharmaceutical giant announced yesterday that it has agreed to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion in upfront cash. The acquisition marks a significant move into psychedelic-based mental health therapies.
🧬 Inside AtaiBeckley's Biotech Pipeline
Lilly is set to pay an additional $1 billion if AtaiBeckley's experimental therapies achieve specific clinical and regulatory milestones, bringing the potential value of the deal to $3.8 billion.
The acquisition secures several high-potential experimental assets:
- BPL-003: A DMT-based nasal spray developed for treatment-resistant depression. It has shown promising efficacy in Phase 2 trials and received FDA Breakthrough Therapy designation last fall.
- EMP-01: An oral drug designed for social anxiety disorder that utilizes a molecular structure similar to MDMA (commonly known as ecstasy).
- VLS-01: A buccal film formulation of DMT in mid-stage clinical development for major depressive disorder.
Here is a look at the proposed clinical roadmap:
[ Drug Compound ] ──► [ Phase 2 / Efficacy ] ──► [ FDA Breakthrough ] ──► [ Phase 3 / Approval ]
(DMT / MDMA) (BPL-003 Nasal Spray) (Breakthrough status) (Lilly-funded trials)
🧠Overcoming the Stigma of Antidepressant Research
This acquisition brings Eli Lilly full circle. Before achieving massive market success with its GLP-1 blockbusters Mounjaro and Zepbound, Lilly was known for Prozac, its blockbuster antidepressant released nearly 40 years ago.
Lilly's chief scientific officer noted that the historical stigma surrounding depression treatments in the 1980s is highly comparable to the current stigma surrounding psychedelic therapy. By throwing its massive resources and corporate weight behind these treatments, Lilly aims to normalize and accelerate clinical adoption.
🔮 A Friendlier Regulatory Landscape
The acquisition comes amidst a shifting regulatory environment. Earlier this year, the FDA fast-tracked research guidelines for psychedelic substances, paving the way for larger clinical trials. Investors had already anticipated this shift, driving AtaiBeckley’s stock price to more than double over the past year.
Lilly’s acquisition of AtaiBeckley is part of a larger plan to spend up to $25 billion on acquisitions this year. The company is actively diversifying its assets across vaccine development, cancer treatments, and sleep therapeutics.
🔗 Reference
- Original Article: Read the full story on Morning Brew
